NASDAQ · HROWHealthcarePharmaceuticals

Harrow financials

$31.40−0.63%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
FY19
Dec 31
Revenue$272.3M$199.6M$130.2M$88.6M$72.5M$48.9M$51.2M
Gross profit$204.4M$150.4M$90.6M$63.2M$54.3M$34.4M$34.4M
Gross margin75.1%75.3%69.6%71.3%74.9%70.4%67.3%
Operating income$30.5M$8.8M$431.0K$1.9M$1.6M$385.0K-$4.8M
Net income-$5.1M-$17.5M-$24.4M-$14.1M-$18.5M-$3.4M$168.0K
Net margin−1.9%−8.8%−18.7%−15.9%−25.5%−6.9%0.3%
Diluted EPS$-0.14$-0.49$-0.75$-0.51$-0.69$-0.13$0.01
EBITDA$49.4M$22.7M$12.4M$5.6M$3.7M$3.9M$5.9M
Operating cash flow$43.9M-$22.2M$3.8M$1.7M$5.1M-$1.1M$950.0K
Free cash flow$43.0M-$23.8M$2.4M-$892.0K$3.3M-$2.0M-$518.0K
Diluted shares36.8M35.7M32.6M27.5M26.8M25.9M26.5M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$72.9M$47.2M$74.1M$96.3M$42.2M$4.3M
Short-term investments$0.00$0.00$8.7M$5.6M$8.5M$28.5M
Total debt$243.2M$219.5M$185.9M$104.2M$71.7M$16.3M
Total assets$399.5M$389.0M$312.2M$157.4M$98.3M$57.5M
Total liabilities$347.4M$319.7M$241.8M$130.1M$87.4M$30.6M
Shareholders' equity$52.1M$69.3M$70.4M$27.2M$10.9M$26.8M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology